Document:

spp_Ex1012

		

			Exhibit 10.12

		

		
			Executive Officer Compensation
		

		
			 
		

		
			Base Salary
		

		
			The following table sets forth the base salary for each named executive officer of Sanchez Midstream Partners GP LLC, the general partner of Sanchez Midstream Partners LP (the “Partnership”).  Each person is an employee of Sanchez Oil & Gas Corporation (“SOG”) and provides services to the Partnership, with the amounts listed being the portion of the salary allocated to the Partnership, effective as of January 1, 2018.
		

			
					
						 

					
					
						 

				
	
					
						Sanchez Production Partners LP, Officer

					
					
						Base Salary

				
	
					
						Gerald F. Willinger

					
						Chief Executive Officer

					
					
						$600,000

				
	
					
						Charles C. Ward

					
						Chief Financial Officer & Secretary

					
					
						$275,000

				
	
					
						Patricio D. Sanchez

					
						President & Chief Operating Officer

					
					
						$400,000

				

		
			 
		

		
			Other Benefits
		

		
			SOG does not maintain a defined benefit pension plan for its employees because it believes that such plans primarily reward longevity rather than performance. SOG provides a basic benefits package generally to all employees, which includes a 401(k) plan, parking costs, and health, disability and life insurance.  In addition, SOG, in its discretion, may permit executive officers to utilize company-owned or chartered aircraft for personal use.  In its discretion, SOG and/or the board of directors of the Partnership’s general partner may award the named executive officers cash bonuses and/or equity compensation.spp_Ex1013

		

			Exhibit 10.13

		

		
			Board Compensation for Directors*
		

		
			 
		

			
					
						Type of Compensation

					
					
						Amount

				
	
					
						Board Cash Retainer

					
					
						$10,000, payable quarterly on the last day of each fiscal quarter, commencing January 1, 2017+

				
	
					
						Equity Grant

					
					
						$100,000 (issued March 31 of each year based on the Partnership’s Common Unit closing price on the NYSE American on such date (or the next trading day if such date is not a trading day)); fully vested upon issuance; any person appointed to the Board shall be issued equity on a pro rata basis from the date of appointment through the following March 31 (with the number of Common Units based on the closing price on the NYSE American on the date of appointment (or the next trading day if such date is not a trading day))

				
	
					
						Board Meeting Fees

					
					
						$1,500 for each meeting attended

				
	
					
						Committee Meeting Fees

					
					
						$1,000 for each substantive meeting of the Audit Committee attended

				
	
					
						 

					
					
						$3,500 for each substantive meeting of the Conflicts Committee attended

				
	
					
						Committee Chair Retainer

					
					
						$3,500 for Audit Committee Chair, payable quarterly on the last day of each fiscal quarter+

					
						$2,500 for Conflicts Committee Chair, payable quarterly on the last day of each fiscal quarter+

				
	
					
						Other Benefits

					
					
						Independent Directors are eligible to participate in the basic health benefits package available to SOG employees.  Additionally the Independent Directors are eligible for reimbursement for life term insurance up to a $500,000 policy face value.

				

		
			*Includes all persons serving as directors, excepting those appointed by the Class B Preferred Holders.
		

		
			+For any person who ceases to serve during the fiscal quarter prior to such payment date, such person shall receive a pro rata amount for the portion of the fiscal quarter so served.kura-ex1010_616.htm

 

Exhibit 10.10

 

Amended and Restated Non-Employee Director Compensation Policy

 

Each member of the Board of Directors (the “Board”) who is not also serving as an employee of Kura Oncology, Inc. (“Kura”) or any of its subsidiaries (each such member, an “Eligible Director”) will receive the compensation described in this Amended and Restated Non-Employee Director Compensation Policy (this “Policy”) for his or her Board service on and following the date of the Company’s 2018 Annual Meeting (the “Effective Date”).  This Policy is effective as of the Effective Date and may be amended at any time in the sole discretion of the Board or the Compensation Committee of the Board.

 

Annual Cash Compensation

 

The annual cash compensation amount set forth below is payable in equal quarterly installments, payable in arrears on the last day of each fiscal quarter in which the service occurred. If an Eligible Director joins the Board or a committee of the Board at a time other than effective as of the first day of a fiscal quarter, each annual retainer set forth below will be pro-rated based on days served in the applicable fiscal year, with the pro-rated amount paid for the first fiscal quarter in which the Eligible Director provides the service, and regular full quarterly payments thereafter. All annual cash fees are vested upon payment. 

 

	
1.
	
Annual Board Service Retainer: 

a.All Eligible Directors: $38,000

 

	
2.
	
Annual Committee Member Service Retainer:

a.Member of the Audit Committee: $7,500

b.Member of the Compensation Committee: $5,000

c.Member of the Nominating & Governance Committee: $3,750

 

	
3.
	
Annual Committee Chair Service Retainer (in addition to Committee Member Service Retainer):

a.Chairman of the Audit Committee: $7,500

b.Chairman of the Compensation Committee: $5,000

c.Chairman of the Nominating & Governance Committee: $3,750

 

Equity Compensation

 

The equity compensation set forth below will be granted under the Kura Oncology, Inc. Amended and Restated 2014 Equity Incentive Plan (the “Plan”). All stock options granted under this Policy will be nonstatutory stock options, with an exercise price per share equal to 100% of the Fair Market Value (as defined in the Plan) of the underlying common stock of Kura on the date of grant, and a term of ten years from the date of grant (subject to earlier termination in connection with a termination of service as provided in the Plan, provided that upon a termination of service other than for death, disability or cause, the post-termination exercise period will be 12 months from the date of termination).

 

 

1.Initial Grant: On the date of the Eligible Director’s initial election to the Board, for each Eligible Director who is first elected to the Board on or following the Effective Date (or, if such date is not a market trading day, the first market trading day thereafter), the Eligible Director will be automatically, and without further action by the Board or Compensation Committee of the Board, granted a stock option for 30,000 shares (the “Initial Grant”).  The shares subject to each Initial Grant will vest in equal annual installments over a three year period such that the option is fully vested on the third anniversary of the date of grant, subject to the Eligible Director’s Continuous Service (as defined in the Plan) through each such vesting date and will vest in full upon a Change in Control (as defined in the Plan).

 

2.Annual Grant: On the date of each Kura’s annual stockholder meeting held after the Effective Date, for each Eligible Director who continues to serve as a non-employee member of the Board (or who is first elected to the Board at such annual stockholder meeting), the Eligible Director will be automatically, and without further action by the Board or Compensation Committee of the Board, granted a stock option for 13,000 shares (the “Annual Grant”). In addition, each Eligible Director who is first elected to the Board following (i) the Effective Date and (ii) the date of Kura’s first annual stockholder meeting, and other than at an annual stockholder meeting will be automatically, and without further action by the Board or Compensation Committee of the Board, granted an Annual Grant, pro-rated for the number of months remaining until the next annual stockholder meeting.  The shares subject to the Annual Grant will vest on the one year anniversary of the date of grant, subject to the Eligible Director’s Continuous Service (as defined in the Plan) through such vesting date and will vest in full upon a Change in Control (as defined in the Plan).

 

2kura-ex1023_180.htm

Exhibit 10.23

***Text Omitted and Filed Separately with the Securities and Exchange Commission.  

Confidential Treatment Requested Under 

17 C.F.R. Sections 200.80(b)(4) and 240.24b-2

 

 

VIA CERTIFIED MAIL

 

August 24, 2017

 

The Regents of the University of Michigan

Office of Research and Sponsored Projects

3003 S. State St. Room 1070

Ann Arbor, MI 48109-1274

 

Attn:  Anthony L. Neilsen, J.D.

 

	
RE:
	
Research Agreement between Kura Oncology, Inc. (“Kura”) and The Regents of the University of Michigan (the “University”) dated February 15, 2015 (the “Research Agreement”)

	

	
(Amendment 6 to the Patent License Agreement dated December 22, 2014)

 

Dear Anthony:

 

Pursuant to Section 8.2 of the Research Agreement, we hereby give notice of the exercise by Kura of its option to obtain an exclusive royalty-bearing license to the University’s interest in the patent application numbered [...***...].  Effective upon this notice, the Patent License Agreement between the University and Kura is deemed amended (Amendment 6) to add the above-referenced patent application to subsection (ii)(a) of the definition of PATENT RIGHTS under such agreement.  

Please let me know if you have any questions.

 

Sincerely,

 

/s/ Annette North

Annette North

SVP, General Counsel

 

cc:  Ed Pagani, Ph.D., Associate Director,
  University of Michigan

 

***Confidential Treatment Requested

3033 Science Park Road, Suite 220, San Diego, CA 92121

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00280-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00280-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00280-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00280-of-00352.parquet"}]]